<DOC>
	<DOCNO>NCT00210964</DOCNO>
	<brief_summary>The purpose study compare clinical cure rate ceftobiprole medocaril ( water-soluble prodrug [ form ] ceftobiprole ) refer ceftobiprole versus comparator treatment patient nosocomial pneumonia .</brief_summary>
	<brief_title>Ceftobiprole Hospital Acquired Pneumonia</brief_title>
	<detailed_description>Ceftobiprole medocaril ( water-soluble prodrug [ form ] ceftobiprole ) , refer ceftobiprole cephalosporin antibiotic anti-MRSA ( Methicillin-Resistant Staphylococcus Aureus ) activity . Ceftobiprole yet approve treatment nosocomial ( hospital-acquired ) pneumonia . This randomized , double-blind , multicenter study ceftobiprole versus comparator ( linezolid plus ceftazidime ) ass effectiveness safety ceftobiprole patient nosocomial pneumonia . The patient randomize receive ceftobiprole plus placebo comparator . The primary endpoint clinical cure rate ceftobiprole test-of-cure visit . The patient receive either ceftobiprole plus placebo comparator 7 14 day ( unless extend discretion medical monitor ) . Patient safety monitor throughout study . In December 2006 , study ( BAP00307 ) another similar study ( BAP00248 , see NCT00229008 ) amend ( change ) create 1 study ( BAP00248/307 ) .Therefore , result report study combine result report study BAP00248 . Patients receive either ceftobiprole plus placebo comparator intravenous infusion 7 14 day ( unless extend discretion medical monitor ) .</detailed_description>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Linezolid</mesh_term>
	<mesh_term>Ceftazidime</mesh_term>
	<mesh_term>Ceftobiprole</mesh_term>
	<mesh_term>Ceftobiprole medocaril</mesh_term>
	<mesh_term>Cephalosporins</mesh_term>
	<criteria>Patients suffer nosocomial pneumonia ventilatorassociated pneumonia Female patient must postmenopausal least 1 year , surgically sterile , practice effective method birth control , entry throughout study , negative serum urine pregnancy test screen Known suspect hypersensitivity relate antibiotic medication Any know suspected condition concurrent treatment would contraindicate prescribe information Treatment investigational drug within 30 day enrollment Prior enrollment study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Ceftobiprole medocaril</keyword>
	<keyword>Nosocominal Pneumonia</keyword>
	<keyword>Ventilator-Associated Pneumonia</keyword>
	<keyword>Cephalosporins</keyword>
	<keyword>Methicillin-Resistant Staphylococcus Aureus</keyword>
</DOC>